| Trial ID: | L1997 |
| Source ID: | NCT02120976
|
| Associated Drug: |
Jtt-252 Or Placebo
|
| Title: |
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: JTT-252 or Placebo|DRUG: JTT-252
|
| Outcome Measures: |
Primary: Number of subjects with adverse events, 22 days|Vital signs and 12 lead ECGs, 22 days|Cmax (maximum concentration), 22 days|t1/2 (elimination half-life), 22 days|AUC (area under the concentration-time curve), 22 days|fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval), 3 days|Plasma glucose, 22 days |
|
| Sponsor/Collaborators: |
Sponsor: Akros Pharma Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
85
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-04
|
| Completion Date: |
2015-03
|
| Results First Posted: |
|
| Last Update Posted: |
2015-05-01
|
| Locations: |
Overland Park, Kansas, United States|Austin, Texas, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02120976
|
